Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
China Medical University Hospital has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution is currently managed by a distinct examiner and a distinct art unit. This indicates a highly focused patenting effort, likely centered on a specific medical or pharmaceutical innovation. By concentrating its efforts in a single art unit, the hospital can develop a deep understanding of the specific examination criteria applied to its technology.
The busiest examiner, COUNTS, GARY W, is assigned 1 busiest examiner pending office action. This figure represents the entirety of the hospital's current pending actions at the USPTO. With only 1 distinct examiner to engage, the hospital can focus its legal resources on the specific requirements and precedents relevant to this single point of contact. Practitioners should recognize that the outcome of this 1 pending office action will define the hospital's current success in the Biotechnology & Pharmaceuticals sector, as there are no other active matters to provide alternative prosecution paths.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUNTS, GARY W | 1 | 59.0% | +29.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037592 | BIOMARKERS FOR PREDICTING IMMUNOGENICITY AND THERAPEUTIC RESPONSES TO ADALIMUMAB IN RHEUMATOID ARTHRITIS PATIENTS | COUNTS, GARY W | 56d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037592 | BIOMARKERS FOR PREDICTING IMMUNOGENICITY AND THERAPEUTIC RESPONSES TO ADALIMUMAB IN RHEUMATOID ARTHRITIS PATIENTS | COUNTS, GARY W | 56d |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037592 | BIOMARKERS FOR PREDICTING IMMUNOGENICITY AND THERAPEUTIC RESPONSES TO ADALIMUMAB IN RHEUMATOID ARTHRITIS PATIENTS | COUNTS, GARY W | 1678 | §101 | Non-Final OA | 56d | Pending | May 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChina Medical University Hospital has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Gary W Counts has the most, with 1 of China Medical University Hospital's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.